GlaxoSmithKline and Innoviva have announced the filing by GSK of a regulatory submission with the European Medicines Agency for once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) for patients with chronic obstructive pulmonary disease (COPD).
This follows the announcement of the submission of a new drug application for FF/UMEC/VI in the US in November 2016. The closed triple combination therapy comprises three medicines: fluticasone furoate, an inhaled corticosteroid (ICS), umeclidinium, a long-acting muscarinic antagonist (LAMA) and vilanterol, a long-acting beta2-adrenergic agonist (LABA), delivered once-daily in GSK’s Ellipta dry powder inhaler.
At 2:28pm: (LON:GSK) GlaxoSmithKline PLC share price was -8p at 1460.5p
Story provided by StockMarketWire.com